Epilepsy Pipeline Assessment 2024: Clinical Trials, FDA Approvals, Therapies, ROA, MOA and Key Companies involved by DelveInsight | Novartis, Pfizer, Sanofi, Takeda Pharmaceutical, Abbott Laboratories, GlaxoSmithKline

(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Epilepsy pipeline constitutes 75+ key companies continuously working towards developing 90+ Epilepsy treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

"Epilepsy Pipeline Insight, 2024" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Epilepsy Market.

The Epilepsy Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Some of the key takeaways from the Epilepsy Pipeline Report: https://www.delveinsight.com/sample-request/epilepsy-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
• Epilepsy Companies across the globe are diligently working toward developing novel Epilepsy treatment therapies with a considerable amount of success over the years.
• Epilepsy companies working in the treatment market are Receptor Life Sciences, Cerebral Therapeutics, Equilibre Biopharmaceuticals, Cerevel Therapeutics, Elium Therapeutics, CombiGen, Ovid Therapeutics, Otsuka Pharmaceutical Co.,Ltd., SK Biopharmaceuticals, Engrail Therapeutics, Amzell, Xenon Pharmaceuticals Inc., and others, are developing therapies for the Epilepsy treatment
• Emerging Epilepsy therapies in the different phases of clinical trials are- RLS103, CT-010, EQU 001, Darigabat, Kv7 Program, CG 01, OV329, OPC-214870, SKL24741, ENX-101, AMZ002, XEN496, and others are expected to have a significant impact on the Epilepsy market in the coming years.
• In January 2023, Amzell has commenced a randomized, open-label study aimed at assessing the superiority of AMZ002 in treating infantile spasms, a rare form of epilepsy. The primary objective of this study is to compare the efficacy and safety of AMZ002 with Vigabatrin in individuals newly diagnosed with infantile spasms (IS).
• In March 2022, Lupin has obtained approval from the United States Food and Drug Administration (FDA) for its abbreviated new drug application (ANDA) for Vigabatrin. This anti-epileptic medication is offered in the form of an oral solution USP (500 mg).
• In March 2022, The medication Ztalmy, developed by Marinus Pharmaceuticals, has been granted approval by the United States Food and Drug Administration (FDA) for the treatment of seizures in individuals diagnosed with CDKL5 deficiency, a genetic type of epilepsy.
• In October 2021, Amzell BV has obtained a special protocol assessment from the FDA for the Phase III trial of their novel injectable therapy targeting Infantile Epileptic Disease. AMZ002, a sterile injectable hormone, aims to introduce a purified synthetic polypeptide as an alternative to the current FDA-approved treatments for managing epileptic seizures.
• In March 2021, Xenon Pharmaceuticals has started a clinical trial involving a randomized, double-blind, placebo-controlled, parallel-group, multicenter study. This trial aims to assess the effectiveness, safety, and tolerance of XEN496 when used as additional treatment in about 40 pediatric patients aged between one month and less than six years old diagnosed with KCNQ2-DEE.

Epilepsy Overview
A chronic neurological illness called epilepsy is typified by recurrent, frequent seizures that cause atypical behavior. Because the causes, severity, and types of seizures vary, it may be classified as a spectrum disorder. The disorder known as epilepsy is characterized by abnormal or excessive electrical discharges from brain cells that impair brain function.

Get a Free Sample PDF Report to know more about Epilepsy Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/epilepsy-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Emerging Epilepsy Drugs Under Different Phases of Clinical Development Include:
• RLS103: Receptor Life Sciences
• CT-010: Cerebral Therapeutics
• EQU 001: Equilibre Biopharmaceuticals
• Darigabat: Cerevel Therapeutics
• Kv7 Program: Elium Therapeutics
• CG 01: CombiGen
• OV329: Ovid Therapeutics
• OPC-214870: Otsuka Pharmaceutical Co.,Ltd.
• SKL24741: SK Biopharmaceuticals
• ENX-101: Engrail Therapeutics
• AMZ002: Amzell
• XEN496: Xenon Pharmaceuticals Inc.

Epilepsy Route of Administration
Epilepsy pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical

Epilepsy Molecule Type
Epilepsy Products have been categorized under various Molecule types, such as
• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy

Epilepsy Pipeline Therapeutics Assessment
• Epilepsy Assessment by Product Type
• Epilepsy By Stage and Product Type
• Epilepsy Assessment by Route of Administration
• Epilepsy By Stage and Route of Administration
• Epilepsy Assessment by Molecule Type
• Epilepsy by Stage and Molecule Type

DelveInsight's Epilepsy Report covers around 90+ products under different phases of clinical development like
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Further Epilepsy product details are provided in the report. Download the Epilepsy pipeline report to learn more about the emerging Epilepsy therapies
https://www.delveinsight.com/sample-request/epilepsy-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Some of the key companies in the Epilepsy Therapeutics Market include:
Key companies developing therapies for Epilepsy are - Novartis AG, Pfizer, Inc., Sanofi SA, Takeda Pharmaceutical Company Limited, Abbott Laboratories, GlaxoSmithKline PLC, Johnson & Johnson, Sunovion Pharmaceuticals Inc., UCB S.A., Sun Pharmaceutical, GW Pharmaceuticals plc, H. Lundbeck A/S, Alkem Labs., Eisai Co., and others.

Epilepsy Pipeline Analysis:
The Epilepsy pipeline report provides insights into
• The report provides detailed insights about companies that are developing therapies for the treatment of Epilepsy with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Epilepsy Treatment.
• Epilepsy key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Epilepsy Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Epilepsy market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Epilepsy drugs and therapies
https://www.delveinsight.com/sample-request/epilepsy-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Epilepsy Pipeline Market Drivers
• Rising awareness and strategic alliance, increasing launch of novel drugs, high burden of epilepsy are some of the important factors that are fueling the Epilepsy Market.

Epilepsy Pipeline Market Barriers
• However, loss of patent protection for branded drugs, high cost of treatment and other factors are creating obstacles in the Epilepsy Market growth.

Scope of Epilepsy Pipeline Drug Insight
• Coverage: Global
• Key Epilepsy Companies: Receptor Life Sciences, Cerebral Therapeutics, Equilibre Biopharmaceuticals, Cerevel Therapeutics, Elium Therapeutics, CombiGen, Ovid Therapeutics, Otsuka Pharmaceutical Co.,Ltd., SK Biopharmaceuticals, Engrail Therapeutics, Amzell, Xenon Pharmaceuticals Inc., and others
• Key Epilepsy Therapies: RLS103, CT-010, EQU 001, Darigabat, Kv7 Program, CG 01, OV329, OPC-214870, SKL24741, ENX-101, AMZ002, XEN496, and others
• Epilepsy Therapeutic Assessment: Epilepsy current marketed and Epilepsy emerging therapies
• Epilepsy Market Dynamics: Epilepsy market drivers and Epilepsy market barriers

Request for Sample PDF Report for Epilepsy Pipeline Assessment and clinical trials
https://www.delveinsight.com/sample-request/epilepsy-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Table of Contents
1. Epilepsy Report Introduction
2. Epilepsy Executive Summary
3. Epilepsy Overview
4. Epilepsy- Analytical Perspective In-depth Commercial Assessment
5. Epilepsy Pipeline Therapeutics
6. Epilepsy Late Stage Products (Phase II/III)
7. Epilepsy Mid Stage Products (Phase II)
8. Epilepsy Early Stage Products (Phase I)
9. Epilepsy Preclinical Stage Products
10. Epilepsy Therapeutics Assessment
11. Epilepsy Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Epilepsy Key Companies
14. Epilepsy Key Products
15. Epilepsy Unmet Needs
16 . Epilepsy Market Drivers and Barriers
17. Epilepsy Future Perspectives and Conclusion
18. Epilepsy Analyst Views
19. Appendix
20. About DelveInsight

Trending Reports:
• Abetalipoproteinemia Market: https://www.delveinsight.com/report-store/abetalipoproteinemia-market
• Polycythemia Market: https://www.delveinsight.com/report-store/polycythemia-vera-market
• Ambulatory Arrhythmia Monitoring Devices Market: https://www.delveinsight.com/report-store/ambulatory-arrhythmia-monitoring-devices-market
• Choroidal Neovascularization Market: https://www.delveinsight.com/report-store/choroidal-neovascularization-market
• Pruritus Market: https://www.delveinsight.com/report-store/pruritus-market
• Cardiopulmonary Bypass Equipment Market: https://www.delveinsight.com/report-store/cardiopulmonary-bypass-equipment-market
• Chemotherapy Induced Anemia Market: https://www.delveinsight.com/report-store/chemotherapy-induced-anemia-market
• Chronic Bronchitis Market: https://www.delveinsight.com/report-store/chronic-obstructive-pulmonary-disease-copd-market
• Clbp Market: https://www.delveinsight.com/report-store/chronic-lower-back-pain-clbp-market
• Hearing Implants Market: https://www.delveinsight.com/report-store/hearing-implants-market
• Neurovascular Devices Market: https://www.delveinsight.com/report-store/neurovascular-devices-interventional-neurology-market
• Pemphigus Vulgaris Market: https://www.delveinsight.com/infographics/pemphigus-vulgaris-market
• Polycythemia Vera Market: https://www.delveinsight.com/report-store/polycythemia-vera-market
• Advanced Renal Cell Carcinoma Market: https://www.delveinsight.com/report-store/advanced-renal-cell-carcinoma-rcc-market
• Airway Stent Market Market: https://www.delveinsight.com/report-store/airway-stent-market
• Allergic Conjunctivitis Market: https://www.delveinsight.com/report-store/allergic-conjunctivitis-market
• Alopecia Areata Market: https://www.delveinsight.com/report-store/alopecia-areata-market
• Alport Syndrome Market: https://www.delveinsight.com/report-store/alport-syndrome-market
• Angioedema Market: https://www.delveinsight.com/report-store/angioedema-market
• Bladder Pain Syndrome Market: https://www.delveinsight.com/report-store/interstitial-cystitis-market
• Bone Densitometers Market: https://www.delveinsight.com/report-store/bone-densitometers-market
• Brain Aneurysm Stents Market: https://www.delveinsight.com/report-store/brain-aneurysm-stents-market
• Calciphylaxis Market: https://www.delveinsight.com/report-store/calciphylaxis-market
• Chronic Inflammatory Demyelinating Polyneuropathy Market: https://www.delveinsight.com/report-store/chronic-inflammatory-demyelinating-polyneuropathy-cidp-market
• Chronic Inflammtory Demyelinating Polyneuropathy Market: https://www.delveinsight.com/report-store/chronic-inflammatory-demyelinating-polyneuropathy-cidp-market
• Chronic Myelogenous Leukemia Market: https://www.delveinsight.com/report-store/chronic-myeloid-leukemia-market
• Cutaneous T-cell Lymphoma Market: https://www.delveinsight.com/report-store/cutaneous-t-cell-lymphoma-ctcl-market
• Defibrillators Market: https://www.delveinsight.com/report-store/defibrillator-market
• Dermal Erythema Market: https://www.delveinsight.com/report-store/dermal-erythema-market
• Eczema Market: https://www.delveinsight.com/report-store/atopic-dermatitis-market

Contact Info:
Ankit Nigam
Assistant Manager (Marketing & Branding)
Email: info@delveinsight.com
428, D21 Corporate Park, Sector-21, Dwarka, New Delhi-110077, India

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

This release was published on openPR.